Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen

by Blumenstein, Brent, Saad, Fred, Hotte, Sebastien, Chi, Kim N, Eigl, Bernhard, Gleave, Martin, Jacobs, Cindy
Published 2013

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer

by Watahiki, Akira, Macfarlane, Robyn J., Gleave, Martin E., Crea, Francesco, Wang, Yuzhuo, Helgason, Cheryl D., Chi, Kim N.
Published 2013

Morphological Differences between Circulating Tumor Cells from Prostate Cancer Patients and Cultured Prostate Cancer Cells

by Park, Sunyoung, Ang, Richard R., Duffy, Simon P., Bazov, Jenny, Chi, Kim N., Black, Peter C., Ma, Hongshen
Published 2014

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer

by Bishop, Jennifer L., Sio, Alexander, Angeles, Arkhjamil, Roberts, Morgan E., Azad, Arun A., Chi, Kim N., Zoubeidi, Amina
Published 2014

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II tria...

by Leibowitz-Amit, Raya, Pintilie, Melania, Khoja, Leila, Azad, Arun A., Berger, Raanan, Laird, A. Douglas, Aftab, Dana T., Chi, Kim N., Joshua, Anthony M.
Published 2016

Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer

by Crea, Francesco, Watahiki, Akira, Quagliata, Luca, Xue, Hui, Pikor, Larissa, Parolia, Abhijit, Wang, Yuwei, Lin, Dong, Lam, Wan L., Farrar, William L., Isogai, Takao, Morant, Rudolf, Castori-Eppenberger, Serenella, Chi, Kim N., Wang, Yuzhuo, Helgason, Cheryl D.
Published 2014

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

by Lallous, Nada, Volik, Stanislav V., Awrey, Shannon, Leblanc, Eric, Tse, Ronnie, Murillo, Josef, Singh, Kriti, Azad, Arun A., Wyatt, Alexander W., LeBihan, Stephane, Chi, Kim N., Gleave, Martin E., Rennie, Paul S., Collins, Colin C., Cherkasov, Artem
Published 2016

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

by Joshua, Anthony M., Shore, Neal D., Saad, Fred, Chi, Kim N., Olsson, Carl A., Emmenegger, Urban, Scholz, Mark, Berry, William, Mukherjee, Som D., Winquist, Eric, Haas, Naomi B., Foley, Margaret A., Dmuchowski, Carl, Perabo, Frank, Hirmand, Mohammad, Hasabou, Nahla, Rathkopf, Dana
Published 2015

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

by Cheng, Heather H., Gulati, Roman, Azad, Arun, Nadal, Rosa, Twardowski, Przemyslaw, Vaishampayan, Ulka N., Agarwal, Neeraj, Heath, Elisabeth I., Pal, Sumanta K., Rehman, Hibba-tul, Leiter, Amanda, Batten, Julia A., Montgomery, R. Bruce, Galsky, Matthew D., Antonarakis, Emmanuel S., Chi, Kim N., Yu, Evan Y.
Published 2015